Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Intermittent IL-2 in HIV
NCT00001474Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 1995
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Optimal duration of each infusion at 1 year and Optimal interval between infusions at 1 year. Started May 1995; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001474.